Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Post-Marketing Surveillance (All Case Surveillance) on Treatment With Alhemo® in Patients With Haemophilia A or Haemophilia B With Inhibitors
Post-Marketing Surveillance (All Case Surveillance) on Treatment With Alhemo® in Patients With Haemophilia A or Haemophilia B With Inhibitors

NCT06285071

Enrolling By InvitationN/A

Sponsor: Novo Nordisk A/S

Conditions: Haemophilia A, Haemophilia B

Interventions: Concizumab

Countries: Japan

The purpose of the study is to investigate the safety and effectiveness of Alhemo® in all participants under real-world clinical practice in Japan. Participants will get Alhemo® as prescribed by the study doctor. The study will last for about 2 years.

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria
Inclusion Criteria:

* Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol)
* The decision to initiate treatment with commercially available Alhemo® has been made by the patient/LAR and the treating physician before and independently from the decision to include the patient in this study
* Male or female patients, regardless of age
* Diagnosis with HAwI/HBwI

Exclusion Criteria:

\- Previous participation in this study. Participation is defined as having given informed consent in this study
Locations (11)
  • Toshima City, Tokyo, Japan
  • Aomori, Japan
  • Fukuoka, Japan
  • Hokkaido, Japan
  • Kagoshima, Japan
  • Kanagawa, Japan
  • Kitakyusyu-shi, Fukuoka, Japan
  • Okinawa, Japan
  • Okinawa, Japan
  • Tokyo, Japan
  • Tokyo, Japan